Herpes Simplex Virus (HSV) Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Virus Type (HSV-1 v/s HSV-2), By Treatment (Drugs v/s Vaccines), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationHerpes Simplex Virus (HSV) Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Virus Type (HSV-1 v/s HSV-2), By Treatment (Drugs v/s Vaccines), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region
VCL-HB01 is a vaccine being developed by the company Vical for the treatment of genital herpes. In a phase II trial, the vaccine was found to be safe and well-tolerated, and was associated with a significant reduction in viral shedding.
Increasing prevalence of HSV Infection
According to the World Health Organization, more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection.
Advancements in technology and research
There has been significant progress in the research and development of new treatment options for HSV infections. This includes the development of new antiviral drugs and innovative therapies such as gene editing, which have the potential to revolutionize HSV treatment. There have been recent advances in the development of novel antiviral drugs for the treatment of HSV infections. These drugs work by inhibiting the replication of the virus and can help to reduce the duration and severity of symptoms. Researchers are exploring the use of gene editing techniques such as CRISPR/Cas9 to target the HSV virus and potentially eliminate it from infected cells. While this approach is still in the early stages of development, it has shown promising results in laboratory studies. There are currently no FDA-approved vaccines for the prevention of HSV infections, but several are in development. These vaccines work by stimulating the body's immune system to recognize and fight the virus and could be an important tool in reducing the overall prevalence of HSV infections. In addition to medical treatments, behavioural interventions such as counselling and education can also be effective in reducing the transmission and impact of HSV infections. These interventions focus on promoting safe sex practices and helping individuals to understand and manage their infection. Overall, there have been several recent advancements in the treatment of HSV infections, including novel antiviral drugs, gene editing, vaccines, topical treatments, and behavioural interventions. These developments hold promise for improving the management and prevention of HSV infections in the future. Researchers are also exploring the use of immune-based therapies, which work by modifying the body's immune response to the virus, for the treatment of HSV infections. These therapies could potentially reduce the frequency and severity of outbreaks and improve quality of life for people with HSV infections. Some immune-based therapies are currently in the clinical development stage.
Growing Healthcare Expenditure
In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus).
Growing focus on preventive measures
Xerese is a topical cream containing acyclovir and hydrocortisone that is used to treat cold sores caused by HSV-1. It was approved by the FDA in 2016.
Market Segmentation
Global Herpes Simplex Virus (HSV) Treatment Market can be segmented by virus type, by treatment, by route of administration, by distribution channel and by region. Based on virus type, the market can be divided into HSV-1 v/s HSV-2. Based on treatment, the market can be divided into Drugs v/s Vaccines. Based on route of administration, the market can be differentiated into Oral, Intravenous, Topical. Based on distribution channel, the market can be segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global herpes simplex virus treatment market on account of growing demand for treatments due to increasing prevalence of herpes simplex virus infection.
Market Players
Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd are some of the leading players operating in the Global Herpes Simplex Virus (HSV) Treatment Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | By Virus Type By Treatment By Route of Administration By Distribution Channel By Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
| Key companies profiled | Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy